Side-effects profile of venetoclax (ABT-199)

Published on

Topics include: Patient Stories

Prof. John Gribben, from the Barts Cancer Institute, London, UK discusses with Deborah Sims, a chronic lymphocytic leukaemia (CLL) patient, the side-effects profile of venetoclax (ABT-199). Deborah is currently enrolled in a clinical trial of obinutuzumab and venetoclax, and at this point, she has received a round of obinutuzumab, and she is discussing with her doctor the potential side-effects of venetoclax. These include gastro-intestinal disruption and tumour lysis (rapid tumour cell death). Debora and Prof. Gribben, also discuss what the doctors and nurses will be looking for to ensure Deborah is responding well to treatment.

To learn more about Deborah's story visit her blog at

View more programs featuring and

Join Our Community Register for Events Read Our Latest Blog

Page last updated on April 12, 2016